Adverse events should be reported. Reporting forms and information can be found at:

Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148.

For more information about Biquelle XL, please click here for the prescribing information.

About Biquelle XL

Biquelle XL is a prolonged-release tablet of quetiapine indicated for the:1

  • Treatment of schizophrenia;

  • Treatment of moderate to severe manic and major depressive episodes in bipolar disorder;

  • Prevention of recurrence of manic or depressive episodes in patients with bipolar disorder who have previously responded to quetiapine;

  • Treatment of major depressive episodes in patients with Major Depressive Disorder who have had sub-optimal response to antidepressant monotherapy as an add-on treatment.

Schizophrenia and medication adherence

The recommended daily dose, for the treatment of schizophrenia and moderate to severe manic episodes of bipolar disorder, is 600 mg, of quetiapine.1

Adherence to medication is essential for the alleviation of symptoms, with effective management of schizophrenia still remaining a significant challenge to clinicians.2-5 Approximately 70-80% of persons with schizophrenia find treatment with first-line antipsychotic medications effective, however, an estimated 50% of those who respond well to medications are non-adherent to treatment regimen.2-5

The recommended daily dosage for treatment of schizophrenia currently necessitates taking two Quetiapine XL 300mg tablets.1,2 Biquelle XL offers a 600mg once a day tablets regime, which may benefit some individual patients with compliance, concordance and adherence to treatment. .2-5

Available as:

  • 50mg prolonged-release tablets

  • 150mg prolonged-release tablets

  • 200mg prolonged-release tablets

  • 300mg prolonged-release tablets

  • 400mg prolonged-release tablets

  • 600mg prolonged-release tablets

Biquelle XL is bioequivalent to Seroquel (quetiapine) XL tablets (Luye Pharma Limited, London, UK).6

Biquelle XL could offer significant cost savings to your practice and integrated care system/board (ICS/B).

Quetiapine 50mg, 150mg, 200mg, 300mg and 400mg prolonged-release tablets are in category C of the UK Drug Tariffs.7

However, the NHS can make up to 56% savings on the cost of category C quetiapine by prescribing Biquelle XL by brand name.7*

Prescribing Biquelle XL by brand could save the NHS £8.7Million per year versus prescribing quetiapine prolonged release tablets generically.8**

Biquelle XL is one of Aspire Pharma’s cost saving prolonged-release products.

In addition, Biquelle XL:

  • Full range of strengths available for Biquelle XL;

  • The only 600mg strength available7;

  • Now available in 30 tablet packs for dispensing or splitting versus 60’s1,7;

  • Available from all mainline wholesalers;

  • Bioequivalent to the originator brand;6

  • Price and supply guaranteed9***

*Based on 56% saving when prescribing Biquelle XL 50, 150, 200, 300 and 400mg tablets only, versus the cost of Category C quetiapine XL on the UK Drug Tariffs. ** Annual cost saving based on modelled market quarterly turnover data x 4 surrounding 42 ICS/ICBS reviewing their generic quetiapine prolonged-release tablet prescriptions to Biquelle XL. ***No change in price subject to no material change to the products or Category C of the UK Drug Tariffs until the 2024 VPAS review.
References: 1) Biquelle XL Summary of product characteristics. 2) Peuskens J. (2011). The management of schizophrenia: focus on extended-release quetiapine fumarate. Neuropsychiatric disease and treatment, 7, 549–564. (accessed April 2023) 3) Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002). Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. The Journal of Clinical Psychiatry, 63(10), 892–909. (accessed April 2023) 4) Acosta, F. J., Hernández, J. L., Pereira, J., Herrera, J., & Rodríguez, C. J. (2012). Medication adherence in schizophrenia. World journal of psychiatry, 2(5), 74–82. (accessed April 2023) 5) El-Mallakh, P., & Findlay, J. (2015). Strategies to improve medication adherence in patients with schizophrenia: the role of support services. Neuropsychiatric disease and treatment, 11, 1077–1090. (accessed April 2023) 6) 1010067149 v 5.0 September 2021 Data on File – Bioequivalence for prolonged-release 7)  UK Drug Tariffs (April 2023) 8) Insypher data: 10100831045 v 13.0 April 2023 CSC XL Range, GPPLPD Date Range: Sep-22 -Nov-22 9) 1010269098 v 16.0 February 2023 Biquelle XL (Quetiapine) Price Guarantee Letter and 1010083058 v 35.0 March 2023 Cost-saving Prolonged-release Range Supply guarantee Letter

More products available
in this range:
Click to view their
individual websites